NCT00241930|UnknownPhase 4
Integrating Buprenorphine Into HIV Treatment
SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model
Loading search results
SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model
Sponsor study identifier
Secondary identifiers
interventional
60
1 country
3
Study Start
September 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
February 2009
Date type not reportedThis date has not been verified as actual or estimated.
We hypothesize that integrating drug treatment into HIV treatment will improve HIV outcomes as well as drug treatment outcomes in heroin users. This study will test this hypothesis by randomizing patients to two groups. The first group will receive HIV treatment and buprenorphine treatment contemporaneously at their HIV clinic. The second group will receive HIV treatment at their HIV clinic, and go to another facility to receive buprenorphine treatment services. We will look at HIV outcomes such as CD4 counts, HIV viral loads, and attendance at appointments and drug treatment outcomes such as receipt of buprenorphine and urine toxicology testing.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2009
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2005
Date type not reportedThis date has not been verified as actual or estimated.
October 17, 2005
Actual (reported)October 19, 2005
Actual (reported)February 2009
Date type not reportedThis date has not been verified as actual or estimated.
1.Impact of integrated care vs nonintegrated care on:
a. Substance use and high-risk transmission behaviors
b. Medical engagement and outcomes
c. Psychosocial indices, such as criminal justice, employment, housing, and education
1. Acceptability of HIV treatment-based buprenorphine therapy
2. Health services utilization
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Alameda County Medical Center HIV Clinic
Oakland, California, 94602, United States
OASIS
Oakland, California, 94612, United States
Diana L Sylvestre, MD
Organization to Achieve Solutions in Substance Abuse (OASIS)
Ruth Finkelstein, ScD
New York Academy of Medicine
First Submitted
October 17, 2005
First Posted
October 19, 2005
Study Start
September 2005
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
February 2009
Date type not reportedCounseling for Primary Care Office-based Buprenorphine
Contact the study team to confirm eligibility.
Fairmont Hospital HIV Clinic
San Leandro, California, 94578, United States
This date has not been verified as actual or estimated.
Last Updated
October 25, 2005
Record last verified: 2005-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: